Three biologics targeting interleukin 5 (IL-5) or its receptor (IL-5Rα) are approved for use in patients with severe asthma. In a meta-analysis, Greek scientists have now investigated the clinical response to anti-IL-5/-5Rα biologics in real-world studies and provided insights into the use of these drugs in clinical practice.
Autoren
- Jens Dehn
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- Chronic lung diseases
Sarcopenia and malnutrition in the context of pneumological rehabilitation
- IBDmatters - Advanced Therapeutic Treatments
Examinations and considerations before therapy
- From symptom to diagnosis
Abdominal pain – chronic pancreatitis
- Acute lymphoblastic leukemia
Addition of blinatumomab to chemotherapy improves survival in children
- Advanced breast cancer
Next-generation SERD therapy with promising results
- Urticaria & urticaria-like exanthema
Case studies from pediatric dermatology
- Vitiligo in children and adolescents
Just don’t bury your head in the sand!
- Psoriasis treatment with biologics